RxDoctor Payments Data

Douglas Beach, MD

Hematology & Oncology · Philadelphia, PANPI 1457598930

Payments from drug & device makers

$332,035in general payments, 2019–2025

Across 90 payments — averaging $3689.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$189K
  • Genentech, Inc.$70K
  • AbbVie$62K
  • Amgen$7K
  • AstraZeneca$2K
  • Astrazeneca UK Limited$2K
  • plus $760 from 9 others

What the payments were for

  • Consulting fees$2,39351%
  • Travel & lodging$1,16325%
  • Food & beverage$96121%
  • Education$1593%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$332,035 in reported general payments places this provider in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,313
Medicare patients
310
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate23$322,502
BrukinsaZanubrutinib14$214,394
Lenalidomide16$213,838
XtandiEnzalutamide12$167,533
EliquisApixaban43$40,227
XareltoRivaroxaban28$27,390
Xtampza ErOxycodone Myristate13$8,629
Oxycodone Hcl61$1,677
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$1,517
Diclofenac Sodium30$1,364
Raloxifene Hcl16$1,073
Tamoxifen Citrate22$895
Hydroxyurea20$632
Anastrozole29$550
Gabapentin38$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$1,943$322,50223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.

Other hematology & oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →